OBJECTIVES: The existence of comorbid diseases among men with newly diagnosed prostate cancer may affect prostate cancer prognosis. METHODS: We identified patients (n = 8114) with a first-time discharge diagnosis of prostate cancer from Danish hospitals between 1995 and 2006. We measured comorbidity using the Charlson Comorbidity Index. RESULTS: The number of patients doubled between 1995 and 2006. The proportion of patients with Charlson scores of 0 (no comorbidity) increased from 62% to 63% of total patients diagnosed, whereas the proportion of patients with Charlson scores of 1 to 2 (moderate comorbidity) decreased from 31% to 29%, and the proportion with Charlson scores of 3 or higher (severe comorbidity) increased from 106 to 227 (7% to 8%). Among patients with a Charlson score of 0, the 1-year survival rate improved from 79% to 94%; among patients with Charlson scores of 1 to 2, the 1-year survival rate increased from 68% to 83%; and in patients with a Charlson score of 3 or higher, this rate increased from 61% to 69%. Compared with patients with Charlson scores of 0, patients with scores of 1 to 2 had age-adjusted 1-year mortality rate ratios (MRRs) of 1.60 in 1995 to 1997, increasing to 2.67 in 2004 to 2006. For patients with Charlson scores of 3 or higher, the adjusted MRR increased from 3.11 in 1995 to 1997 to 5.08 in 2004 to 2006. CONCLUSIONS: Comorbidity was present in more than one-third of prostate cancer patients and was a negative prognostic factor. Although prostate cancer survival generally has improved in Denmark in recent years, no improvement was found among those with high levels of comorbidity.
OBJECTIVES: The existence of comorbid diseases among men with newly diagnosed prostate cancer may affect prostate cancer prognosis. METHODS: We identified patients (n = 8114) with a first-time discharge diagnosis of prostate cancer from Danish hospitals between 1995 and 2006. We measured comorbidity using the Charlson Comorbidity Index. RESULTS: The number of patients doubled between 1995 and 2006. The proportion of patients with Charlson scores of 0 (no comorbidity) increased from 62% to 63% of total patients diagnosed, whereas the proportion of patients with Charlson scores of 1 to 2 (moderate comorbidity) decreased from 31% to 29%, and the proportion with Charlson scores of 3 or higher (severe comorbidity) increased from 106 to 227 (7% to 8%). Among patients with a Charlson score of 0, the 1-year survival rate improved from 79% to 94%; among patients with Charlson scores of 1 to 2, the 1-year survival rate increased from 68% to 83%; and in patients with a Charlson score of 3 or higher, this rate increased from 61% to 69%. Compared with patients with Charlson scores of 0, patients with scores of 1 to 2 had age-adjusted 1-year mortality rate ratios (MRRs) of 1.60 in 1995 to 1997, increasing to 2.67 in 2004 to 2006. For patients with Charlson scores of 3 or higher, the adjusted MRR increased from 3.11 in 1995 to 1997 to 5.08 in 2004 to 2006. CONCLUSIONS: Comorbidity was present in more than one-third of prostate cancerpatients and was a negative prognostic factor. Although prostate cancer survival generally has improved in Denmark in recent years, no improvement was found among those with high levels of comorbidity.
Authors: Navatha Shree Polavaram; Samikshan Dutta; Ridwan Islam; Arup K Bag; Sohini Roy; David Poitz; Jeffrey Karnes; Lorenz C Hofbauer; Manish Kohli; Brian A Costello; Raffael Jimenez; Surinder K Batra; Benjamin A Teply; Michael H Muders; Kaustubh Datta Journal: Bone Res Date: 2021-05-14 Impact factor: 13.567
Authors: Christina G Jespersen; Mette Nørgaard; Truls E Bjerklund Johansen; Mette Søgaard; Michael Borre Journal: BMC Cancer Date: 2011-12-15 Impact factor: 4.430
Authors: Zachary Klaassen; Roberto Muller; Qiang Li; Alexander J Tatem; Sherita A King; Stephen J Freedland; Rabii Madi; Martha K Terris; Kelvin A Moses Journal: Int Sch Res Notices Date: 2014-08-24
Authors: Joo Yong Lee; Dae Hun Lee; Nam Hoon Cho; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Seung Choul Yang; Kang Su Cho Journal: Yonsei Med J Date: 2014-03 Impact factor: 2.759
Authors: Sunil Gupta; Truyen Tran; Wei Luo; Dinh Phung; Richard Lee Kennedy; Adam Broad; David Campbell; David Kipp; Madhu Singh; Mustafa Khasraw; Leigh Matheson; David M Ashley; Svetha Venkatesh Journal: BMJ Open Date: 2014-03-17 Impact factor: 2.692